Märkte

COSCIENS Biopharma Inc.

CSCI · NASDAQ Global Market · USD

2,72USD

−0,00 (−0,00 %)Stand 4. Sept., 20:00

Vortag 2,72

Kennzahlen

Eröffnung
2,72
Vortag
2,72
Tagesspanne
2,72 – 2,72
52 Wochen
1,75 – 4,6054
Ø Volumen
9718
Börsenwert
8,57 Mio. $
KGV
-0,5
Gewinn je Aktie (TTM)
-6,21
Dividendenrendite
0,0 %
Beta
1,9
Nächste Zahlen
–

Finanzen

USDFY 2024FY 2023FY 2022FY 2021FY 2020
Umsatz13,78 Mio.7,14 Mio.14,57 Mio.13,49 Mio.11,86 Mio.
Herstellungskosten6,98 Mio.4,21 Mio.6,02 Mio.5,28 Mio.5,88 Mio.
Bruttogewinn6,8 Mio.2,94 Mio.8,56 Mio.8,21 Mio.5,98 Mio.
Forschung und Entwicklung8,3 Mio.2,04 Mio.1,37 Mio.3,04 Mio.1,48 Mio.
Vertrieb und Verwaltung10,45 Mio.5,53 Mio.2,87 Mio.2,58 Mio.2,66 Mio.
Operatives Ergebnis−18,28 Mio.−4,63 Mio.4,32 Mio.−10,96 Mio.1,66 Mio.
EBITDA−13,49 Mio.−2,29 Mio.6,14 Mio.4,18 Mio.3,04 Mio.
Nettogewinn−15,31 Mio.−3,49 Mio.3,45 Mio.2,64 Mio.1,46 Mio.
Gewinn je Aktie (verwässert)-5,93-1,891,861,330,85

Bewertung

Letzte 12 Monate

KGV
-0,5
Kurs-Umsatz-Verhältnis
0,6
Kurs-Buchwert-Verhältnis
0,5
PEG
0,0
Bruttomarge
49,3 %
Operative Marge
−132,6 %
Nettomarge
−111,1 %
Verschuldungsgrad
0,2
EV/EBITDA
0,4
Eigenkapitalrendite
−89,5 %
Kapitalrendite (ROIC)
−65,0 %
Free-Cashflow-Rendite
−183,5 %
FY 2024FY 2023FY 2022FY 2021FY 2020
Bruttomarge49,3 %41,1 %58,7 %60,9 %50,4 %
Operative Marge−132,6 %−64,8 %29,6 %−81,3 %14,0 %
Nettomarge−111,1 %−48,8 %23,7 %19,6 %12,3 %
KGV-0,5-4,23,25,79,0
Kurs-Umsatz-Verhältnis0,52,11,01,01,2
Kurs-Buchwert-Verhältnis0,50,70,60,60,8
Verschuldungsgrad0,20,10,10,10,1
Liquidität 3. Grades3,36,51,61,01,2
Dividendenrendite0,0 %0,0 %0,0 %0,0 %0,0 %
Unternehmenswert−6,93 Mio.10,25 Mio.6,7 Mio.9,88 Mio.12,14 Mio.
EV/EBITDA0,5-4,51,12,44,0
Eigenkapitalrendite−116,3 %−16,6 %14,5 %12,1 %8,7 %
Kapitalrendite (ROIC)−65,0 %−16,2 %17,7 %−73,9 %9,7 %
Free-Cashflow-Rendite−220,0 %−22,5 %32,9 %15,8 %21,5 %

Wachstum

FY 2024FY 2023FY 2022FY 2021FY 2020
Umsatz+93,0 %−51,0 %+8,1 %+13,7 %+20,3 %
Bruttogewinn+131,4 %−65,7 %+4,2 %+37,3 %+43,4 %
Operatives Ergebnis−294,9 %−207,2 %+139,4 %−761,0 %+469,4 %
Nettogewinn−339,3 %−201,1 %+30,6 %+81,3 %+267,9 %
Gewinn je Aktie−213,8 %−201,6 %+39,8 %+56,5 %+277,1 %
Freier Cashflow−376,1 %−167,1 %+124,1 %−26,9 %+120,6 %
Dividende je Aktie0,0 %0,0 %0,0 %0,0 %0,0 %

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Aug. 2025Apr. 2025März 2025Nov. 2024Aug. 2024Mai 2024März 2024Nov. 2023
Gewinn je Aktie · Erwartet–-3,48–-3,48-3,28-3,24-3,88-2,44
Gewinn je Aktie · Tatsächlich-0,85-2,15-4,64-1,85-0,64-4,74-4,64-3,40
Abweichung–+38,22 %–+46,84 %+80,49 %−46,30 %−19,59 %−39,34 %
Umsatz · Tatsächlich2,02 Mio.1,5 Mio.3,32 Mio.1,9 Mio.2,3 Mio.4000100.000–

Dividenden und Splits

Keine Dividenden gezahlt.

Aktiensplits

  • 3. Mai 20241:4
  • 21. Juli 20221:25
  • 20. Nov. 20151:100
  • 5. Okt. 20121:6

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

–

Vergleichbare Unternehmen

Über das Unternehmen

COSCIENS Biopharma Inc. is a specialized biopharmaceutical company dedicated to the global development and commercialization of innovative therapeutic and diagnostic products. Its operations extend across Canada, Switzerland, Ireland, Denmark, Germany, the United States, and other international territories. The company's flagship product is Macrilen (macimorelin), an orally administered peptidomimetic ghrelin receptor (GHSR-1a) agonist. This compound works by stimulating growth hormone secretion through its interaction with the GHSR-1a receptor, primarily serving for the diagnosis of both adult and childhood-onset growth hormone deficiency. It also shows promise in other endocrinology and oncology applications. Its pipeline includes AEZS-150, a delayed-clearance parathyroid hormone fusion polypeptide currently undergoing preclinical evaluation for the management of chronic hypoparathyroidism. Another preclinical candidate, AEZS-130, is being investigated for its potential in treating amyotrophic lateral sclerosis (ALS). COSCIENS has established a license and research collaboration with the University of Wuerzburg. This partnership aims to develop, produce, and market AIM biologicals targeting neuromyelitis optica spectrum disorder, alongside conducting preclinical research into their potential for Parkinson's disease treatment. To further its commercial efforts for Macrilen, the company has licensing agreements with Consilient Health Ltd. and NK MEDITECH Ltd. for its development and commercialization, as well as a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood specifically for Macrilen's diagnostic application in pediatric and adult growth hormone deficiency. Further collaborations include an agreement with The University of Sheffield in the United Kingdom, focused on the development, manufacturing, and commercialization of parathyroid hormone fusion polypeptides designed to address chronic hypoparathyroidism. Originally incorporated in 1990 as Aeterna Zentaris Inc., the company officially rebranded as COSCIENS Biopharma Inc. in August 2024. Its corporate headquarters are located in Toronto, Canada.

Führung

  • Gilles R. GagnonPresident, Chief Executive Officer & Director
  • Giuliano La FrattaSenior Vice President of Finance & Chief Financial Officer
  • Michel RegnierSenior Vice President of Technical operations, MD of Ceapro Inc. & Chief Technology Officer
  • Nicola AmmerChief Medical Officer & Senior Vice President of Clinical Development
  • Matthias GerlachSenior Vice President Manufacturing and Supply Chain & Head of Production
  • Michael TeifelSenior Vice President of GmbH & Chief Scientific Officer
CEO
Anna Elizabeth Biehn
Mitarbeitende
40
Hauptsitz
Toronto, ON, CA
Sektor
Healthcare
Branche
Biotechnology
Börsengang
18. Juli 1996
Website
cosciensbio.com

Nachrichten

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.